Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) is now available.
Imricor Medical Systems, Inc. has achieved significant regulatory milestones in Europe with the approval of its NorthStar system and second-generation products under the stringent EU-MDR, leading to a commercial launch and increased hospital engagement. In the United States, the company has submitted the NorthStar 510(k) Premarket Notification to the FDA, marking a strategic entry point into the US market. Despite some delays in the PMA approval process for certain products, Imricor’s prioritization of NorthStar’s approval is expected to align well with its sales cycle, supporting uninterrupted revenue growth and market expansion.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. operates in the medical technology industry, focusing on the development and commercialization of MRI-compatible products. The company’s primary products include the NorthStar system, ablation catheters, and various capital equipment designed for use in interventional cardiac magnetic resonance (iCMR) labs. Imricor is committed to expanding its market presence in Europe and the United States, with a strong emphasis on regulatory approvals and commercial launches.
Average Trading Volume: 381,505
See more data about IMR stock on TipRanks’ Stock Analysis page.